Cholinergic aspects of schizophrenia

British Journal of Psychiatry

Volumn 174, Issue FEB. SUPPL. 37, 1999, Pages 7-11

  Tandon, Rajiv ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; CLOZAPINE;

CHOLINERGIC TRANSMISSION; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEUROTRANSMISSION; PATHOPHYSIOLOGY; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA;

EID: 0033028364     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/s0007125000293586     Document Type: Review

References (43)

1. Andreasen, N. C. & Olsen, S. (1982) Negative vs positive schizophrenia: definition and validation. Archives of General Psychiatry, 39, 789-794.
2. Angrist, B., Rotrosen, J. & Gershon, S. (1980) Differential effects of amphetamine and neuroleptics on negative versus positive symptoms in schizophrenia. Psychopharmocotogy, 72, 17-19.
3. Bolden, C., Cusack, B. & Richelson, E. (1991) Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in the CHO-KI cells. European Journal of Pharmacology, 1921, 205-206.
4. _ , _ & Richelson, E. (1992) Antagonism by antimuscarinic and neuroleptic compounds at the cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. Journal of Pharmacology and Experimental Therapeutics, 160, 379-389.
5. Buchsbaum, M. S. (1990) The frontal lobes, basal ganglia, and temporal lobes as sites for schizophrenia. Schizophrenia Bulletin, 16, 379-389.
6. Carlsson, A. (1974) Antipsychotic drugs and catecholamine synapses. Journal of Psychiatric Research, 11, 57-64.
7. Carpenter, W.T., Jr, Heinrichs, D.W. & Wagman, A. M. I. (1988) Deficit and nondeficit forms of schizophrenia: the concept. American Journal of Psychiatry, 145, 578-583.
8. Chouinard, G., Annable, L., Mercier, P., et al (1987) Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms. Psychopharmacology Bulletin, 23, 221-226.
9. Cohen, L. H., Thale, T. & Tissenbaum, M. J. (1944) Acetylcholine treatment of schizophrenia. Archives of Neurology and Psychiatry, 51, 171-175.
10. Crow, T.J. (1980) Molecular pathology of schizophrenia: more than one disease process? British Medical Journal, 280, 1-9.
11. Fayen, M., Goldman, M. B., Moulthrop, M. A., et al (1988) Differential memory function with dopaminergic versus anticholinergic treatment of drug-induced extrapyramidal symptoms. American Journal of Psychiatry, 145, 483-486.
12. Fisch, R. Z. (1987) Trihexyphenldyl abuse: therapeutic implications for negative symptoms of schizophrenia. Acta Psychiatrica Scadinavica, 75, 91-94.
13. Friedhoff, A. J. & Alpert, M. (1973) A dopaminergic-cholinergic mechanism in production of psychotic symptoms. Biologicol Psychiatry, 6, 165-169.
14. Goff, D. C., Amico, E., Dreyfuss, D., et al (1994) A placebo-controlled trial of trihexyphenidyl in unmedicated patients with schizophrenia. American Journal of Psychiatry, 151, 429-431.
15. Hinze-Selch, D., Mullington, J., Orth, A., et al (1997) Effects of clozapine on sleep: a longitudinal study. Biological Psychiatry, 42, 260-266.
16. Janowsky, D. S., El-Yousef, M. K., Davis, J. M., et al (1973) Antagonist effects of physostigmine and methylphenidate in man. American Journal of Psychiatry, 130, 1370-1376.
17. Jibson, M. D. & Tandon, R. (1996) A summary of new research findings on the new antipsychotic drugs. Essential Psychopharmocology, 1, 27-37.
18. Johnstone, E. C., Crow, T. J., Ferrier, I. N., et al (1983) Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychological Medicine, 13, 513-527.
19. Kane, J. M., Honigfeld, G., Singer, J., et al (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789-796.
20. Meltzer, H. Y., Chai, B. L., Thompson, P. A., et al (1994) Effect of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol, or thioridazine. Journal of Pharmacology and Experimental Therapeutics, 268, 1452-1461.
21. _ & Stahl, S. M. (1976) The dopamine hypothesis of schizophrenia: a review. Schizophrenia Bullelin, 2, 19-76.
22. Richelson, E. (1984) Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. Journal of Clinical Psychiatry, 45, 331-336.
23. Riemann, D., Gann, H., Fleckenstein, P., et al (1994) Effect of RS 86 on REM latency in schizophrenia. Psychiatry Research, 38, 89-92.
24. Rivest, R. & Marsden, C. A. (1991) Muscarinic antagonists attenuate the increase in accumbens and striatum dopamine metabolism produced by clozapine but not by haloperidol. British Journal of Pharmacology, 104, 234-238.
25. Singh, M. M., Kay, S. R. & Opler, L. A. (1987) Anticholinergic-neuroleptic antagonism in terms of positive and negative symptoms of schizophrenia: implications for psychobiological subtyping. Psychological Medicine, 17, 39-48.
26. Tandon, R. (1997) Effects of atypical antipsychotics on polysomnographic measures in schizophrenia. Bibliotheca Psychiatrica, 167, 219-222.
27. _ , Greden, J. F. & Silk, K. R. (1988) Treatment of negative schizophrenic symptoms with trihexyphenidyl. Journal of Clinical Psychopharmacobgy, 8, 212-215.
28. _ & Greden, J. F. (1989) Cholinergic hyperactivity and negative schizophrenic symptoms: a model of dopaminergic/cholinergic interactions in schizophrenia. Archives of General Psychiatry, 46, 745-753.
29. _ , Goldman, R., Goodson, J., et al (1990a) Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia. Biological Psychiatry, 27, 1323-1326.
30. _ , Mann, N., Eisner, W., et al (1990b) Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients. Psychiatry Research, 31, 235-241.
31. _ , Greden, J. F. Goodson, J., et al (1991a) Muscarinic hyperactivity in schizophrenia: relationship to positive and negative symptoms. Schizophrenia Research, 4, 23-30.
32. _ , Mazzara, C., DeQuardo, J., et al (1991b) Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome. Biological Psychiatry, 29, 953-964.
33. _ , DeQuardo, J. R., Goodson, J., et al (1992a) Effect of anticholinergics on positive and negative symptoms in schizophrenia. Psychopharmacology Bulletin, 28, 297-302.
34. _ , Shipley, J. E., Taylor, S., et al (1992b) Electroencephalographic sleep abnormalities in schizophrenia: relationship to positive/negative symptoms and prior neuroleptic treatment. Archives of General Psychiatry, 49, 185-194.
35. _ & Kane, J. M. (1993) Neuropharmacologic basis for clozapine's unique profile. Archives of General Psychiatry, 50, 157-159.
36. _ , Goldman, R., DeQuardo, J. R., et al (1993a) Covariance of positive and negative symptoms during clozapine treatment in schizophrenia. Journal of Psychiatric Research, 27, 341-347.
37. _ , Ribeiro, S. C. M., DeQuardo, J. R., et al (1993b) Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication. Biological Psychiatry, 34, 495-497.
38. _ , Jibson, M., Taylor, S. F., et al (1995) The pathophysiology of positive and negative symptoms in schizophrenia. In Contemporary Issues in the Treatment of Schizophrenia (eds C. Shriqui & H. A. Nasrallah), pp. 190-224. Washington, DC: American Psychiatric Press.
39. _ , Lewis, C., Taylor, S. F., et al (1996) Relationship between DST nonsuppression and shortened REM latency in schizophrenia. Biological Psychiatry, 40, 660-663.
40. _ , DeQuardo, J. R., & Taylor, S. F. (1999) Neurobiology of schizophrenia. In Textbook of Psychopharmacology (ed. J. Ananth). New Delhi: Jaypee Brothers (in press).
41. Yeoman, O. (1995) Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology, 12, 3-16.
42. Zeng, X. P., Le, F. & Richelsen, E. (1997) Muscarinic M4 receptor activation by some atypical antipsychotic drugs. European Journal of Pharmacology, 321, 349-354.
43. Zorn, S. H., Jones, S. B., Ward, K. M., et al (1994) Clozapine is a potent and selective muscarinic M4 receptor agonist. European Journal of Pharmacology, 269, R1-R2.